ABOUABDELLAH, AHMED,CHEREZE, NATHALIE,FAYOL, AUDE,SAADY, MOURAD,VACHE, JULIEN,VERONIQUE, CORINNE,YAICHE, PHILIPPE
申请号：
NZ59274009
公开号：
NZ592740A
申请日:
2009.11.13
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
592740 Disclosed herein is a compound of the general formula (I), wherein the variables are defined in the specification, and the use thereof in the treatment of a pathology in which the endogenous cannabinoids and/or any other substrate metabolised by the enzyme FAAH are involved, such as acute or chronic pain, vertigo, vomiting, nausea, eating disorders, neurological and psychiatric pathologies, acute or chronic neurodegenerative diseases, epilepsy, sleeping disorders, cardiovascular diseases, renal ischaemia, cancers, immune system disorders, allergic diseases, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, ocular complaints, pulmonary complaints, gastrointestina1 diseases or urinary incontinence. Specific embodiments of the compound of the general formula (I) include: 3-Methylcarbamoylisoxazol-5-ylmethyl (+)-[1-(4-chloropyrimidin-2-yl)pyrrolidin-3-ylmethyl] carbamate 3-Carbamoylisoxazol-5-ylmethyl { 2-[1-(4-trifluoromethyltrifluoromethylpyrimidin-2-yl) azetidin-3-yl] ethyl} carbamate, and Ethyl 5-[1-(6-chloroquinolin-2-yl)-4-fluoropiperidin-4-ylmethylcarbamoyloxymethyl] isoxazole-3-carboxylate
